News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,711 Results
Type
Article (13945)
Company Profile (304)
Press Release (247462)
Section
Business (79356)
Career Advice (151)
Deals (13190)
Drug Delivery (34)
Drug Development (50328)
Employer Resources (31)
FDA (5682)
Job Trends (5116)
News (144134)
Policy (10018)
Tag
Academia (901)
Alliances (21525)
Alzheimer's disease (756)
Approvals (5661)
Artificial intelligence (68)
Bankruptcy (97)
Best Places to Work (4522)
Biotechnology (249)
Breast cancer (109)
Cancer (888)
Cardiovascular disease (71)
Career advice (132)
CAR-T (73)
Cell therapy (217)
Clinical research (40137)
Collaboration (308)
Compensation (128)
COVID-19 (1006)
C-suite (78)
Cystic fibrosis (66)
Data (983)
Diabetes (85)
Diagnostics (1207)
Drug discovery (56)
Earnings (29004)
Events (47193)
Executive appointments (247)
FDA (6047)
Funding (306)
Gene editing (63)
Gene therapy (163)
GLP-1 (310)
Government (1065)
Healthcare (6543)
Infectious disease (1043)
Inflammatory bowel disease (98)
IPO (7197)
Job creations (859)
Job search strategy (127)
Layoffs (188)
Legal (1375)
Lung cancer (130)
Lymphoma (62)
Manufacturing (86)
Medical device (2558)
Medtech (2559)
Mergers & acquisitions (6128)
Metabolic disorders (257)
Neuroscience (999)
NextGen Class of 2024 (2004)
Non-profit (847)
Northern California (1091)
Obesity (140)
Opinion (91)
Parkinson's disease (75)
Patents (61)
People (25103)
Phase I (14150)
Phase II (18664)
Phase III (11818)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (201)
Real estate (1409)
Regulatory (8281)
Research institute (931)
Southern California (976)
Startups (1964)
United States (8655)
Vaccines (164)
Weight loss (83)
Date
Last 7 days (364)
Last 30 days (1422)
Last 365 days (20528)
2024 (20440)
2023 (22413)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16923)
Australia (2856)
California (2474)
Canada (809)
China (203)
Colorado (91)
Connecticut (103)
Europe (36445)
Florida (271)
Georgia (71)
Illinois (153)
Indiana (61)
Kansas (55)
Maryland (330)
Massachusetts (1955)
Minnesota (101)
New Jersey (630)
New York (682)
North Carolina (419)
Northern California (1091)
Ohio (82)
Pennsylvania (474)
South America (207)
Southern California (976)
Texas (278)
Washington State (247)
261,711 Results for "lycia therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracellular Protein Degraders to the Clinic
Lycia Therapeutics, Inc., a leader in extracellular protein degradation, announced the completion of an oversubscribed $106.6 million Series C financing.
May 13, 2024
·
3 min read
Business
Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics
Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, announced it has entered into a collaboration agreement with Lycia Therapeutics, a leader in extracellular protein degradation.
December 4, 2023
·
2 min read
Biotech Bay
Lycia Therapeutics to Present at Jefferies 2023 Healthcare Conference
Lycia Therapeutics, Inc., a leader in extracellular protein degradation, announced that Aetna Wun Trombley, Ph.D., President and Chief Executive Officer of Lycia, will present a corporate overview at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 2:00 pm ET in New York.
June 5, 2023
·
1 min read
Business
Lycia Therapeutics Founder Dr. Carolyn Bertozzi Awarded 2022 Nobel Prize in Chemistry
Lycia Therapeutics, Inc. announced that founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in Chemistry.
October 5, 2022
·
2 min read
Business
Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific Officer
Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the recent appointment of Steve Staben, Ph.D., as Chief Scientific Officer.
February 28, 2022
·
3 min read
Business
Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders
Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia’s proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology.
August 25, 2021
·
4 min read
Biotech Bay
Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures
Lycia Therapeutics, Inc. today announced the completion of an oversubscribed $70 million Series B financing.
September 9, 2021
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Business
Lilly and Lycia Ink Collaboration and Licensing Deal Worth Up to $1.6 Billion
Lycia will be receiving a $35 million upfront payment from Lilly and is eligible for over $1.6 billion in potential milestone payments.
August 26, 2021
·
2 min read
·
Ellen Bombela
Deals
Versant Ventures Launches Lycia Therapeutics with $50 Million
Biotechnology company Lycia Therapeutics, Inc. exited stealth mode with a $50 million commitment from founding investor Versant Ventures.
June 9, 2020
·
8 min read
1 of 26,172
Next
